Fig. 2.

NorUDCA suppresses cell size and frequency of intrahepatic effector CD8⁺ T cells in LCMV clone 13 model.

(A) Changes in body weight over time. (B) Serum BA, ALT, AST, ALP. (C) Representative plots and quantitative analysis of intrahepatic virus-specific CD8⁺ T cells. (D) Liver LCMV virus titer. (E) Representative plots and quantitative analysis of intrahepatic CD8⁺ T cells. Cells recognizing the LCMV-GP33 peptide in the context of MHC class I presentation are labeled as GP33⁺. (F) Representative high-power-field multicolor immunofluorescence staining of CD3 and pRPS6^Ser235/236 of liver slides of indicated groups. Data are summary of 3 independent experiments. At least 3 biologically independent animals were used per group during experiments. Quantitative data are presented as mean±SE. p values were calculated by one-way ANOVA corrected with Tukey post-hoc test and in A were calculated by two-way ANOVA. ∗p <0.05, ∗∗p <0.01, ∗∗∗p <0.001, ∗∗∗∗p <0.0001. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; BA, bile acid; LCMV, lymphocytic choriomeningitis virus; NorUDCA, 24-norursodeoxycholic acid; PV, portal vein; Rapa, rapamycin.